Furthermore, in a randomized phase II study, several GC patients that showed high CD44 median score had a complete response when treated concurrently with vismodegib, 5-FU, oxaliplatin, and leucovorin, but the combination treatment was not effective in patients expressing low CD44 median score, suggesting a major role of Hh signaling in CSC-mediated chemoresistance [157]. The gene discussed is CD44; the disease is gastric cancer.